News MedinCell LIQUIDNET SYSTEMS

Equities

FR0004065605

Real-time Estimate Tradegate Other stock markets 02:23:13 17/05/2024 pm IST			5-day change	1st Jan Change
14.01 ^EUR	0.00%		0.00%	0.00%

15/05	Medincell: share price falls after disappointing clinical study	CF
15/05	Transcript : MedinCell S.A. - Special Call

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medincell: share price falls after disappointing clinical study	15/05	CF
Transcript : MedinCell S.A. - Special Call	15/05
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial	14/05	BU
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial	14/05	CI
Medincell to Host Videoconference on May 15, 2024, at 10:30 AM CEST to Discuss Company's Latest News, Outlook, and R&D Activities	13/05	BU
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia	09/05	AQ
Medincell: share price rises on resumption of trading	09/05	CF
CAC40: remains in green in a neglected market	08/05	CF
Medincell: positive results in schizophrenia	08/05	CF
Medincell Listing Temporarily Suspended on Euronext Paris	08/05	MT
Teva and Medincell's schizophrenia drug meets main goal of late-stage study	08/05	RE
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia	08/05	BU
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia	08/05	BU
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia	08/05	BU
Teva Pharmaceuticals and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-?749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia	08/05	CI
CAC40: in green, builds on previous day's momentum	08/05	CF
MedinCell S A : Inside Information / Other news releases	08/05	PU
Medincell: listing suspended pending a press release	08/05	CF
Medincell announces the suspension of listing of its shares on Euronext Paris	08/05	BU
Medincell: share price rises following agreement with AbbVie	17/04	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News MedinCell LIQUIDNET SYSTEMS

Equities

FR0004065605

Summary

Filters